ROMJ Fundamental Analysis - RUBICON ORGANICS INC

Fundamental Rating

Taking everything into account, ROMJ scores 5 out of 10 in our fundamental rating. ROMJ was compared to 34 industry peers in the Pharmaceuticals industry. ROMJ has an average financial health and profitability rating. ROMJ is valued quite expensive, but it does show an excellent growth. These ratings could make ROMJ a good candidate for growth investing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ROMJ has reported negative net income.

In the past year ROMJ had a positive cash flow from operations.

In the past 5 years ROMJ always reported negative net income.

The reported operating cash flow has been mixed in the past 5 years: ROMJ reported negative operating cash flow in multiple years.

1.2 Ratios

Looking at the Return On Assets, with a value of -1.79%, ROMJ is in line with its industry, outperforming 50.00% of the companies in the same industry.

ROMJ has a better Return On Equity (-2.64%) than 61.76% of its industry peers.

Looking at the Return On Invested Capital, with a value of 21.77%, ROMJ belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.

The Average Return On Invested Capital over the past 3 years for ROMJ is significantly above the industry average of 7.83%.

The last Return On Invested Capital (21.77%) for ROMJ is above the 3 year average (19.33%), which is a sign of increasing profitability.

		Industry Rank	Sector Rank
ROA	-1.79%
ROE	-2.64%
ROIC	21.77%

ROA(3y)-4.91%

ROA(5y)-14.11%

ROE(3y)-7.24%

ROE(5y)-22.2%

ROIC(3y)19.33%

ROIC(5y)N/A

1.3 Margins

The Operating Margin of ROMJ (26.59%) is better than 100.00% of its industry peers.

ROMJ has a better Gross Margin (58.85%) than 88.24% of its industry peers.

ROMJ's Gross Margin has improved in the last couple of years.

		Industry Rank	Sector Rank
OM	26.59%
PM (TTM)	N/A
GM	58.85%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y1.88%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), ROMJ is creating value.

Compared to 1 year ago, ROMJ has more shares outstanding

ROMJ has more shares outstanding than it did 5 years ago.

Compared to 1 year ago, ROMJ has an improved debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of 1.60, we must say that ROMJ is in the distress zone and has some risk of bankruptcy.

ROMJ has a better Altman-Z score (1.60) than 85.29% of its industry peers.

ROMJ has a debt to FCF ratio of 6.91. This is a slightly negative value and a sign of low solvency as ROMJ would need 6.91 years to pay back of all of its debts.

ROMJ has a better Debt to FCF ratio (6.91) than 67.65% of its industry peers.

ROMJ has a Debt/Equity ratio of 0.22. This is a healthy value indicating a solid balance between debt and equity.

ROMJ has a Debt to Equity ratio of 0.22. This is comparable to the rest of the industry: ROMJ outperforms 55.88% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.22
Debt/FCF	6.91
Altman-Z	1.6

ROIC/WACC2.19

WACC9.95%

2.3 Liquidity

A Current Ratio of 3.16 indicates that ROMJ has no problem at all paying its short term obligations.

The Current ratio of ROMJ (3.16) is better than 79.41% of its industry peers.

A Quick Ratio of 1.69 indicates that ROMJ should not have too much problems paying its short term obligations.

ROMJ has a better Quick ratio (1.69) than 70.59% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	3.16
Quick Ratio	1.69

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ROMJ shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 69.01%, which is quite impressive.

Looking at the last year, ROMJ shows a very strong growth in Revenue. The Revenue has grown by 29.78%.

The Revenue has been growing by 29.14% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)69.01%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%83.53%

Revenue 1Y (TTM)29.78%

Revenue growth 3Y29.14%

Revenue growth 5YN/A

Sales Q2Q%39.21%

3.2 Future

ROMJ is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 41.42% yearly.

Based on estimates for the next years, ROMJ will show a very strong growth in Revenue. The Revenue will grow by 27.72% on average per year.

EPS Next Y-75%

EPS Next 2Y41.42%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year10.58%

Revenue Next 2Y18.65%

Revenue Next 3Y27.72%

Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ROMJ. In the last year negative earnings were reported.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

100.00% of the companies in the same industry are more expensive than ROMJ, based on the Enterprise Value to EBITDA ratio.

ROMJ's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. ROMJ is cheaper than 67.65% of the companies in the same industry.

		Industry Rank	Sector Rank
P/FCF	24.89
EV/EBITDA	2.15

4.3 Compensation for Growth

ROMJ has a very decent profitability rating, which may justify a higher PE ratio.

ROMJ's earnings are expected to grow with 41.42% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y41.42%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ROMJ does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

RUBICON ORGANICS INC

TSX-V:ROMJ (8/18/2025, 7:00:00 PM)

0.52

-0.02 (-3.7%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)05-27 2025-05-27

Earnings (Next)08-18 2025-08-18

Inst Owners2.9%

Inst Owner ChangeN/A

Ins Owners41.69%

Ins Owner ChangeN/A

Market Cap34.93M

Analysts80

Price Target1.12 (115.38%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)2.3%

Revenue NY rev (3m)2.3%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.67
P/FCF	24.89
P/OCF	10.6
P/B	0.93
P/tB	0.99
EV/EBITDA	2.15

EPS(TTM)-0.02

EYN/A

EPS(NY)0

Fwd EYN/A

FCF(TTM)0.02

FCFY4.02%

OCF(TTM)0.05

OCFY9.44%

SpS0.78

BVpS0.56

TBVpS0.52

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-1.79%
ROE	-2.64%
ROCE	30.24%
ROIC	21.77%
ROICexc	26.22%
ROICexgc	27.97%
OM	26.59%
PM (TTM)	N/A
GM	58.85%
FCFM	2.69%

ROA(3y)-4.91%

ROA(5y)-14.11%

ROE(3y)-7.24%

ROE(5y)-22.2%

ROIC(3y)19.33%

ROIC(5y)N/A

ROICexc(3y)24.75%

ROICexc(5y)N/A

ROICexgc(3y)26.66%

ROICexgc(5y)N/A

ROCE(3y)26.85%

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y1.88%

GM growth 5YN/A

F-Score5

Asset Turnover0.94

Health

		Industry Rank	Sector Rank
Debt/Equity	0.22
Debt/FCF	6.91
Debt/EBITDA	0.48
Cap/Depr	58.09%
Cap/Sales	3.63%
Interest Coverage	14.7
Cash Conversion	19.24%
Profit Quality	N/A
Current Ratio	3.16
Quick Ratio	1.69
Altman-Z	1.6

F-Score5

WACC9.95%

ROIC/WACC2.19

Cap/Depr(3y)93.56%

Cap/Depr(5y)171.69%

Cap/Sales(3y)7.51%

Cap/Sales(5y)22.12%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)69.01%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%83.53%

EPS Next Y-75%

EPS Next 2Y41.42%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)29.78%

Revenue growth 3Y29.14%

Revenue growth 5YN/A

Sales Q2Q%39.21%

Revenue Next Year10.58%

Revenue Next 2Y18.65%

Revenue Next 3Y27.72%

Revenue Next 5YN/A

EBIT growth 1Y50.65%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-76.82%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y510.77%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-11.13%

OCF growth 3YN/A

OCF growth 5YN/A

RUBICON ORGANICS INC (ROMJ.CA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens